Loading data for REVB — first visit, this takes a few seconds.
Revelation Biosciences, Inc.
0.99 -0.01 (-1.00%)
0.99 +0.00%
- Market Cap
- $3.95M
- Volume
- 3.44K
- Dividend yield
- n/a
- Next earnings date
- Nov 5, 2026
Revelation Biosciences, Inc. (REVB) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0.87 | -$0.04 | +96.90% |
Metrics
- Bid
- 0.68
- Market Cap
- 3.95M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -19.2M
- -0.14
- 27.03
- 0.04
- -0.34
- P/B (ttm)
- 0.39
- P/S (ttm)
- n/a
- Earnings Date
- Nov 5, 2026
- Ask
- 1.29
- Volume
- 3,445
- Avg. Volume (20D)
- 41,020
- Open
- 1.00
- Previous Close
- 1.00
- Day's Range
- 0.99 - 1.00
- 52-Week Range
- 0.88 - 7.60
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Revelation Biosciences, Inc.
View profile →Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2020
Employees 8
Stock Exchange NasdaqCM
Ticker Symbol REVB
Website https://www.revbiosciences.com